GoodRx made drug-price comparison free and billed pharmacy benefit managers instead

Pharmacy benefit managers negotiate discounted drug prices with pharmacies on behalf of insurers, but those negotiated rates were invisible to anyone paying cash — the same medication could cost wildly different amounts at two pharmacies a block apart, and uninsured or high-deductible patients had no tool to compare them. Founders Doug Hirsch and Trevor Bezdek saw a patient with no way to shop for a price that already existed somewhere in the system, just not for them.

Charging patients a subscription or lookup fee to access pricing information would have reproduced the same barrier GoodRx was trying to remove — people avoiding a cost-comparison tool because using it cost money defeats the purpose. GoodRx needed a way to surface real negotiated prices to cash-paying patients without charging the patients for the privilege of finding them.

GoodRx built a free platform aggregating PBM-negotiated pricing across more than 70,000 pharmacies, letting any patient pull up a coupon and pay the discounted rate at checkout. When a patient uses a coupon, the pharmacy processes it through the PBM as if it were an insured claim, and the PBM shares a portion of its processing fee with GoodRx.

Routed cash purchases through the PBM's claims pipeline to expose the discount already there, and got paid from the PBM's existing processing fee.

The discount already existed inside the PBM's system; patients just couldn't see it.

Routing cash purchases through the same claims pipeline as insured purchases let patients reach the rate that was already there.

The PBM had no added cost to serve cash customers this way, making it painless to share a portion of its processing fee with GoodRx.

GoodRx was paid a slice of a fee the PBM was already collecting, not a new charge layered onto the patient's purchase.

When needed info sits inside an intermediary's system, don't charge the customer; route access through that intermediary's existing fee.

Profitable since 2013, GoodRx reached a $2.85B valuation and says it has saved consumers over $20 billion cumulatively. GoodRx proved that transparency itself could be monetized by the intermediaries who controlled pricing rather than by the patients who benefited from seeing it, a structure now widely studied in health-policy research on drug pricing.